Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - December 2016

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Ferric maltol (Feraccru®) has been rejected for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD). The submitting company did not present sufficiently robust clinical and economic analyses to gain acceptance.

Hydrocortisone (Plenadren®) has been rejected for use in the treatment of adrenal insufficiency in adults. The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - December 2016' on Email Share 'SMC Update - December 2016' on Delicious Share 'SMC Update - December 2016' on Digg Share 'SMC Update - December 2016' on Facebook Share 'SMC Update - December 2016' on Google+ Share 'SMC Update - December 2016' on reddit Share 'SMC Update - December 2016' on StumbleUpon Share 'SMC Update - December 2016' on Twitter

atomic-wealth

No Comments to “SMC Update - December 2016”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,211 spam comments.

atomic-wealth
fond-illness
summer